
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 991 | 900 | 925 | 1249 | 1290 | 1365 |
Fund Return | -0.94% | -9.97% | -7.51% | 7.69% | 5.22% | 3.16% |
Place in category | 159 | 159 | 114 | 38 | 36 | 26 |
% in Category | 76 | 80 | 62 | 12 | 21 | 31 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
PIMegatrend Selection Z USD | 10.05B | 5.52 | 6.18 | 9.13 | ||
PIMegatrend Selection R USD | 10.05B | 1.13 | 2.65 | 5.22 | ||
Pictet Global Megatrend Selection P | 10.05B | 1.27 | 3.59 | 6.17 | ||
PIMegatrend Selection I USD | 10.05B | 1.42 | 4.52 | 7.08 | ||
PIMegatrend Selection P dy USD | 10.05B | 1.27 | 3.59 | 6.17 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Franklin Biotech Discovery Nacc | 82.32M | 1.89 | 0.99 | 1.49 | ||
Equities L Biotechnology Class R US | 1.19B | 3.48 | 8.71 | 5.94 | ||
Candriam Equities Biotech C USD Cap | 1.19B | 3.56 | 7.84 | 5.10 | ||
LU0133359157 | 1.19B | 3.53 | 7.41 | 4.64 | ||
Equities L Biotechnology Class I US | 1.19B | 2.92 | 2.58 | 5.59 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Gilead | US3755581036 | 6.57 | 107.25 | -4.57% | |
Insmed | US4576693075 | 5.17 | 69.18 | -5.66% | |
argenx ADR | US04016X1019 | 4.87 | 555.11 | -5.92% | |
Regeneron Pharma | US75886F1075 | 3.55 | 573.45 | -6.09% | |
SpringWorks | US85205L1070 | 3.08 | 39.09 | -9.24% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review